Phase I/IIa study in subjects with Retinitis Pigmentosa
A first, prospective, open, phase I/IIa human study of the safety and tolerability of human retinal progenitor cells (hRPC) transplanted into the subretinal space in subjects with Retinitis Pigmentosa (RP).
This is a prospective open phase I/II study to treat RP patients with transplanted human retinal progenitor cells. Participants will only be treated in one eye.
Main inclusion criteria
Adult men and women who are healthy (apart from their retinitis pigmentosa)
Patients’ visual acuity should be between 20/50 and 20/800 and be similar in both eyes
The aim of the study is to determine the safety and tolerability of human retinal progenitor cell transplantation in RP patients.
About the treatment
Subretinal stem cell injection in one eye. All the participants will receive the treatment and this will only be in one eye.